Open AccessCAR T‑cell therapy for gastric cancer: Potential and perspective (Review)
Author(s) -
Bo Long,
Long Qin,
Boya Zhang,
Qiong Li,
Long Wang,
Xiangyan Jiang,
Hui-Li Ye,
Genyuan Zhang,
Zeyuan Yu,
Jiao Zhang
Publication year - 2020
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2020.4982
Subject(s) - chimeric antigen receptor , cancer , clinical trial , oncogene , cell cycle , immunotherapy , medicine , immunology , biology , cancer research , oncology , bioinformatics
Gastric cancer (GC) is one of the most frequently diagnosed digestive malignancies and is the third leading cause of cancer‑associated death worldwide. Delayed diagnosis and poor prognosis indicate the urgent need for new therapeutic strategies. The success of chimeric antigen receptor (CAR) T‑cell therapy for chemotherapy‑refractory hematological malignancies has inspired the development of a similar strategy for GC treatment. Although using CAR T‑cells against GC is not without difficulty, results from preclinical studies remain encouraging. The current review summarizes relevant preclinical studies and ongoing clinical trials for the use of CAR T‑cells for GC treatment and investigates possible toxicities, as well as current clinical experiences and emerging approaches. With a deeper understanding of the tumor microenvironment, novel target epitopes and scientific‑technical progress, the potential of CAR T‑cell therapy for GC is anticipated in the near future.